Evofem Biosciences will consolidate its shares today at a ratio of 1 to 15. Trading of the securities, taking into account the reverse split, will begin on May 6 of this year. The consolidation will reduce the number of shares of common stock outstanding from 187,699,564 to 12,513,304.